You are here
News & Events
Vertex Provides Update on Ongoing All-Oral Studies of VX-135 in Hepatitis C
-European Study: 12-week dosing complete in 100 mg and 200 mg VX-135 dose groups in combination with ribavirin in Phase 2 study; 70% and 80%, respectively, of patients achieved undetectable HCV RNA by week 4 and treatment was well tolerated with no discontinuations or serious adverse events reported through 12 weeks-
-New Zealand Study: dosing ongoing in Phase 2 study of 100 mg and 200 mg of VX-135 in combination with daclatasvir, an NS5A replication complex inhibitor-
Vertex recently completed dosing of 100 mg and 200 mg of VX-135 in
combination with ribavirin as part of the 12-week Phase 2 study in
"Developing safe and effective medicines for patients is our goal," said
Ongoing Studies of VX-135
Multiple studies of VX-135 as part of all-oral treatment regimens are ongoing, including:
U.S. Study of VX-135 in Combination with Ribavirin:
Dosing of 100 mg of VX-135 in combination with ribavirin as part of a
12-week Phase 2 study in
the United Statesis ongoing, and evaluation of this dose group is continuing as planned. Ten patients with genotype 1 hepatitis C are enrolled in this dose group, and all patients have now completed at least 10 weeks of treatment. Complete safety and efficacy results from the 100 mg arm of the study are expected to be available in the second half of 2013. Under the partial clinical hold, Vertex plans to complete evaluation of the 100 mg dose of VX-135 but will not evaluate a 200 mg dose of VX-135 in the United Stateswithout authorization from the FDA. At the request of the FDA, Vertex expects to complete submission of additional clinical, preclinical and pharmacokinetic data from ongoing VX-135 studies in the fourth quarter.
European Study of VX-135 in Combination with Ribavirin: Dosing
of 100 mg and 200 mg of VX-135 in combination with ribavirin as part
of a 12-week Phase 2 study in
Europeis complete, and all patients are in the post-treatment follow-up period. Ten patients with genotype 1 hepatitis C were enrolled in each dose group and all 20 patients completed 12 weeks of treatment. Both the 100 mg and 200 mg doses were well tolerated, no serious adverse events have been reported and no liver or cardiac safety issues have been identified. All patients achieved undetectable HCV RNA during the 12-week dosing period, and 70 percent and 80 percent of patients in the 100 mg and 200 mg dosing arms, respectively, had undetectable HCV RNA within four weeks of initiating treatment. HCV RNA was undetectable at the end of the treatment period in all patients with available data. Complete safety and efficacy results from the 100 and 200 mg arms of the study are expected to be available in the second half of 2013. Following completion of enrollment in the 100 mg and 200 mg arms of the European study, the study was amended to evaluate a 400 mg dose of VX-135 in combination with ribavirin in ten patients. Elevated liver enzymes were observed in three of ten patients in this dose group, including one serious adverse event, and the 400 mg arm of the study was discontinued. Following the discontinuation of dosing, liver enzyme levels returned to baseline in all three patients.
Study of 100 and 200 mg Doses of VX-135 in Combination with
Vertexand Bristol Myers Squibb Company (BMS) recently initiated dosing in New Zealandin a Phase 2 study of VX-135 in combination with daclatasvir, an NS5A replication complex inhibitor being developed by BMS. This first part of the study is evaluating 100 mg and 200 mg doses of VX-135 in combination with daclatasvir as part of 12-week treatment regimens in approximately 20 people with genotype 1 hepatitis C. Pending data from the initial cohort of patients, Vertex and BMS plan to expand the study to enroll additional patients with both genotypes 1 and 3. Safety and efficacy results from the first part of the study are expected to be available in early 2014.
VX-135 in Combination with Simeprevir: A drug-drug
interaction study of VX-135 in combination with simeprevir in healthy
volunteers is complete. A combination study of VX-135 and simeprevir
is planned for the second half of 2013 in patients with genotype 1
hepatitis C, pending availability of additional data. Simeprevir
(TMC435) is a once-daily investigational hepatitis C protease
inhibitor being jointly developed by
Janssen R&D Irelandand Medivir AB.
- Termination of Collaboration with GlaxoSmithKline (GSK): In June, Vertex and GSK mutually decided to cease the collaboration for a Phase 2 study of VX-135 and GSK-2336805 and prioritize other projects. The preclinical and early-stage clinical data support continued development of VX-135 and of GSK-2336805.
VX-135 is a uridine nucleotide analogue pro-drug designed to inhibit the
replication of the hepatitis C virus by acting on the NS5B polymerase.
Vertex gained worldwide rights to ALS-2200, known as VX-135 in Phase 2
studies, through an exclusive licensing agreement signed with
Vertex creates new possibilities in medicine. Our team discovers, develops and commercializes innovative therapies so people with serious diseases can lead better lives.
Vertex scientists and our collaborators are working on new medicines to cure or significantly advance the treatment of hepatitis C, cystic fibrosis, rheumatoid arthritis and other life-threatening diseases.
Founded more than 20 years ago in
Vertex Special Note Regarding Forward-Looking Statements
This press release contains forward-looking statements as defined in the
Private Securities Litigation Reform Act of 1995, including, without
limitation, Dr. Kauffman's statements in the third paragraph of the
press release and statements regarding (i) Vertex's expectation that it
will complete submission of additional clinical, preclinical and
pharmacokinetic data in the fourth quarter of 2013; (ii) the plan to
complete the evaluation of the 100 mg dose of VX-135 in
VRTX — GEN
News Provided by Acquire Media